An AI experiment at the FDA is being conducted to fast-track evaluation processes for obesity drugs. Specifically, the FDA is leveraging machine learning to analyze clinical trial data while Novo Nordisk faces challenges competing with other firms like Sanofi. This could redefine drug approval timelines in healthcare.
Read More:
- š www.statnews.com